NO20006041L - N-Benzodioxanylmethyl-1-piperidylmethylamine compounds with affinity for 5-HT receptors - Google Patents
N-Benzodioxanylmethyl-1-piperidylmethylamine compounds with affinity for 5-HT receptorsInfo
- Publication number
- NO20006041L NO20006041L NO20006041A NO20006041A NO20006041L NO 20006041 L NO20006041 L NO 20006041L NO 20006041 A NO20006041 A NO 20006041A NO 20006041 A NO20006041 A NO 20006041A NO 20006041 L NO20006041 L NO 20006041L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- compounds
- drug
- disease
- piperidylmethylamine
- Prior art date
Links
- LKEKJOULEGVDHP-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-(piperidin-1-ylmethyl)methanamine Chemical class O1C(COC2=C1C=CC=C2)CNCN1CCCCC1 LKEKJOULEGVDHP-UHFFFAOYSA-N 0.000 title 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Forbindelser med formel I. omfattende farmasøytisk akseptable salter derav hvor R representerer H eller F, deres fremstilling og anvendelse av dem ved behandling av depresjon, angst, psykoser, Parkinson's sykdom, fedme, hypertensjon, Tourette's syndrom, seksuell dysfunksjon, medikamentavhengighet, medikament-misbruk, kognitive lidelser, Alzheimer's sykdom, senil demens, tvangs-nevrotisk adferd, panikk-anfall, spiseforstyrrelser, anoreksi, kardiovaskulære og cerebrovaskulære lidelser, migrene, ikke-insulinavhengig diabetes mellitus, hyperglykemi, forstoppelse, arrytmi, lidelser i det neuroendocrine system, stress, prostatisk hypertrofi, medikament-fremkalte ekstrapyramidale symptomer eller spastisitet; er beskrevet.Compounds of formula I. comprising pharmaceutically acceptable salts thereof wherein R represents H or F, their preparation and use in the treatment of depression, anxiety, psychosis, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug dependence, drug abuse. , cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive disorder, panic attacks, eating disorders, anorexia, cardiovascular and cerebrovascular disorders, migraines, non-insulin dependent diabetes mellitus, hyperglycemia, constipation, arrhythmia, neuroendocrine disorders, prostatic hypertrophy, drug-induced extrapyramidal symptoms or spasticity; is described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811879.7A GB9811879D0 (en) | 1998-06-03 | 1998-06-03 | Therapeutic agents |
| PCT/EP1999/003648 WO1999062902A1 (en) | 1998-06-03 | 1999-05-26 | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006041D0 NO20006041D0 (en) | 2000-11-29 |
| NO20006041L true NO20006041L (en) | 2000-11-29 |
Family
ID=10833098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006041A NO20006041L (en) | 1998-06-03 | 2000-11-29 | N-Benzodioxanylmethyl-1-piperidylmethylamine compounds with affinity for 5-HT receptors |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1087964A1 (en) |
| JP (1) | JP2002517392A (en) |
| KR (1) | KR20010052526A (en) |
| CN (1) | CN1304408A (en) |
| AR (1) | AR018622A1 (en) |
| AU (1) | AU4369599A (en) |
| BG (1) | BG104988A (en) |
| BR (1) | BR9910927A (en) |
| CA (1) | CA2333756A1 (en) |
| CO (1) | CO5021190A1 (en) |
| GB (1) | GB9811879D0 (en) |
| HR (1) | HRP20010005A2 (en) |
| HU (1) | HUP0102233A2 (en) |
| ID (1) | ID27067A (en) |
| IL (1) | IL139552A0 (en) |
| NO (1) | NO20006041L (en) |
| PL (1) | PL344594A1 (en) |
| SK (1) | SK17602000A3 (en) |
| TR (1) | TR200003569T2 (en) |
| WO (1) | WO1999062902A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| JP2003532729A (en) * | 2000-05-12 | 2003-11-05 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Piperazine and piperidine compounds |
| EP1284731A1 (en) * | 2000-05-12 | 2003-02-26 | Solvay Pharmaceuticals B.V. | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| JP2007536302A (en) * | 2004-05-05 | 2007-12-13 | エフ．ホフマン−ラ ロシュ アーゲー | Arylsulfonylbenzodioxanes useful for modulating 5-HT6 receptor, 5-HT2A receptor, or both |
| CA2597616A1 (en) | 2005-02-17 | 2006-08-24 | Wyeth | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681325B1 (en) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | DERIVATIVES OF AMINOMETHYL-4 PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
| FR2701479B1 (en) * | 1993-02-11 | 1995-05-12 | Pf Medicament | New heterocyclic derivatives of 4-aminomethyl piperidine, their preparation and their therapeutic use. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
-
1998
- 1998-06-03 GB GBGB9811879.7A patent/GB9811879D0/en not_active Ceased
-
1999
- 1999-05-26 WO PCT/EP1999/003648 patent/WO1999062902A1/en not_active Ceased
- 1999-05-26 AU AU43695/99A patent/AU4369599A/en not_active Abandoned
- 1999-05-26 TR TR2000/03569T patent/TR200003569T2/en unknown
- 1999-05-26 CA CA002333756A patent/CA2333756A1/en not_active Abandoned
- 1999-05-26 SK SK1760-2000A patent/SK17602000A3/en unknown
- 1999-05-26 IL IL13955299A patent/IL139552A0/en unknown
- 1999-05-26 BR BR9910927-1A patent/BR9910927A/en not_active IP Right Cessation
- 1999-05-26 HR HR20010005A patent/HRP20010005A2/en not_active Application Discontinuation
- 1999-05-26 JP JP2000552113A patent/JP2002517392A/en active Pending
- 1999-05-26 KR KR1020007013670A patent/KR20010052526A/en not_active Withdrawn
- 1999-05-26 PL PL99344594A patent/PL344594A1/en not_active Application Discontinuation
- 1999-05-26 CN CN99806908A patent/CN1304408A/en active Pending
- 1999-05-26 EP EP99926434A patent/EP1087964A1/en not_active Ceased
- 1999-05-26 ID IDW20002519A patent/ID27067A/en unknown
- 1999-05-26 HU HU0102233A patent/HUP0102233A2/en unknown
- 1999-06-03 CO CO99035020A patent/CO5021190A1/en unknown
- 1999-06-03 AR ARP990102619A patent/AR018622A1/en not_active Application Discontinuation
-
2000
- 2000-11-27 BG BG104988A patent/BG104988A/en unknown
- 2000-11-29 NO NO20006041A patent/NO20006041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010005A2 (en) | 2001-12-31 |
| ID27067A (en) | 2001-02-22 |
| AR018622A1 (en) | 2001-11-28 |
| PL344594A1 (en) | 2001-11-05 |
| BG104988A (en) | 2001-11-30 |
| SK17602000A3 (en) | 2001-08-06 |
| TR200003569T2 (en) | 2001-04-20 |
| GB9811879D0 (en) | 1998-07-29 |
| CN1304408A (en) | 2001-07-18 |
| IL139552A0 (en) | 2002-02-10 |
| JP2002517392A (en) | 2002-06-18 |
| KR20010052526A (en) | 2001-06-25 |
| EP1087964A1 (en) | 2001-04-04 |
| WO1999062902A1 (en) | 1999-12-09 |
| NO20006041D0 (en) | 2000-11-29 |
| HUP0102233A2 (en) | 2002-05-29 |
| AU4369599A (en) | 1999-12-20 |
| CO5021190A1 (en) | 2001-03-27 |
| BR9910927A (en) | 2001-02-20 |
| CA2333756A1 (en) | 1999-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69423767D1 (en) | 1,4-Benzodioxane derivatives with affinity for D2 receptors and useful in the treatment of psychoses | |
| AR002830A1 (en) | Novel substituted piperazine compounds and procedure for preparing them | |
| DE69705608D1 (en) | TROPANDERIVATES, THEIR PRODUCTION AND USE | |
| NO20042141L (en) | Therapeutic quinolone compounds with 5-HT antagonistic properties | |
| WO2004022558A3 (en) | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders | |
| NO20006041L (en) | N-Benzodioxanylmethyl-1-piperidylmethylamine compounds with affinity for 5-HT receptors | |
| NZ313164A (en) | Benzodioxan-2-ylmethyl derivatives substituted by heterocyclyl-carboxamide and medicaments | |
| WO2002085896A8 (en) | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | |
| WO2001072741A3 (en) | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders | |
| NO993172L (en) | Sulfonamide compounds with 5-HT receptor activity | |
| Corbel et al. | 1-Benzazepine derivatives acting as ATP-dependent potassium-channels antagonists | |
| Enzensperger et al. | Dopamine/Serotonin Receptor Ligands. 13: Homologization of a Benzindoloazecine-Type Dopamine Receptor Antagonist Modulates the Affinities for Dopamine D1− D5 Receptors | |
| NO20051617L (en) | Piperidine derivatives of heterocycle-fused benzodioxanes with antidepressant activity | |
| MX9709509A (en) | Condensed thiazole derivatives, having 5-ht receptor affinity. | |
| RU2000133316A (en) | N-BENZODHYOXANYLMETHYL-1-PIPERIDYL-METHYLAMINES possess an affinity for 5-HT receptors | |
| AR005368A1 (en) | HETEROARILCARBOXAMIDES COMPOUNDS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THE APPLICATION OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES, A METHOD FOR TREATING DISEASES WITH SUCH COMPOUNDS AND THE PROCEDURES FOR PREPARING SUCH COMPOUNDS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |